Table 1 Descriptive characteristics of 43 urothelial carcinoma of the bladder patients treated with radical cystectomy and bilateral lymphadenectomy.
Age (years) | |
Range, median | 50–86, 71 |
Gender [n (%)] | |
Male | 32 (74.4) |
Female | 11 (25.6) |
Clinical tumor stage [n (%)] | |
cTa, cTis | 2 (4.9) |
cT1 | 6 (14.6) |
cT2 | 32 (78.0) |
cT3 | 1 (2.4) |
Clinical tumor grade [n (%)] | |
cG2 | 4 (9.8) |
cG3 | 37 (90.2) |
Intravesical chemo- and/or immunotherapy prior to RC [n (%)] | |
No | 33 (80.5) |
Yes | 8 (19.5) |
Number of TURB prior to RC | |
Range, median | 1–5, 1 |
Days between last TURB and RC | |
Range, median | 7–480, 45 |
Pathologic tumor stage [n (%)] | |
pT0, pTa, pTis | 1 (2.3) |
pT1 | 3 (7.0) |
pT2 | 17 (39.5) |
pT3 | 12 (27.9) |
pT4 | 10 (23.3) |
Combined tumor stage [n (%)] | |
Localized (pT ≤ 2) | 21 (48.8) |
Advanced (pT3–4) | 22 (51.2) |
Combined disease stage [n (%)] | |
≤ pT2 and pN0 | 19 (44.2) |
≥ pT3 or pN1-3 | 24 (55.8) |
Pathologic tumor grade [n (%)] | |
G3 | 42 (97.7) |
Concomitant carcinoma in situ [n (%)] | |
Absent | 23 (53.5) |
Present | 20 (46.5) |
Lymphovascular invasion [n (%)] | |
Absent | 29 (67.4) |
Present | 14 (32.6) |
Microvessel invasion [n (%)] | |
Absent | 37 (86.0) |
Present | 6 (14.0) |
Lymph node status [n (%)] | |
pN0 | 27 (62.8) |
pN1–3 | 16 (37.2) |
Number of lymph nodes removed | |
Range, median | 0–44, 12 |
Soft tissue surgical margin status [n (%)] | |
Negative | 35 (81.4) |
Positive | 8 (18.6) |
Urothelial carcinoma histology [n (%)] | |
Pure UCB | 28 (65.1) |
Presence of squamous cell differentiation | 7 (16.3) |
Presence of non-squamous cell differentiation | 8 (18.6) |
Presence of incidental prostate cancer in the RC specimen [n (%)] | |
No | 23 (53.5) |
Yes | 20 (46.5) |
Adjuvant chemotherapy [n (%)] | |
Not administered | 29 (67.4) |
Administered | 14 (32.6) |
Adjuvant chemotherapy regimen [n (%)] | |
Cisplatin-based | 6 (14.0) |
Carboplatin-based | 8 (18.6) |
